APL patients treated with As2O3 at Nagoya University Hospital
| No. . | Age, y . | Sex . | Diagnosis . | Treatments prior to As2O3 . | Disease status at As2O3 . | Treatments after As2O3 . | Outcome . | Survival after As2O3 . | As2O3 resistance . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 61 | M | M3v | A+CT | Rel1 | (−) | D | 6 y, 1 mo | + |
| 2 | 35 | M | M3 | A+CT | Rel1 | sib-PBSCT | A | 3 y, 8 mo | − |
| 3 | 30 | M | M3 | A+CT | Rel2 | auto-PBSCT | A | 6 y, 9 mo | − |
| 4 | 41 | M | M3 | A+CT | Rel1 | auto-PBSCT | A | 5 y, 8 mo | − |
| 5 | 62 | M | M3 | A+CT, HD-Ara-C | Rel3 | CBT | D | 10 mo | − |
| 6 | 42 | F | M3 | A+CT, aPBSCT | Rel2 | CBT | D | 4 mo | + |
| 7 | 46 | F | M3 | A+CT | 2nd CR | auto-PBSCT | A | 6 y, 7 mo | − |
| 8 | 54 | F | M3 | A+CT | Rel2 | auto-PBSCT | A | 5 y, 9 mo | − |
| 9 | 19 | M | M3 | A+CT | Rel1 | UR-BMT | A | 6 y, 1 mo | − |
| 10 | 42 | M | M3 | A+CT, UR-BMT | Rel3 | DLI | A | 6 y | − |
| 11 | 61 | M | M3v | A+CT | Rel1 | (−) | D | 4 mo | − |
| 12 | 48 | M | M3 | A+CT, HD-Ara-C | Rel2 | auto-PBSCT | A | 4 y, 9 mo | − |
| 13 | 39 | M | M3v | A+CT, UR-BMT | Rel3 | CBT | D | 5 mo | − |
| 14 | 20 | M | M3 | A+CT | Rel1 | auto-PBSCT | A | 4 y, 9 mo | − |
| 15 | 36 | M | M3 | A+CT | Rel1 | auto-PBSCT | A | 4 y, 2 mo | − |
| No. . | Age, y . | Sex . | Diagnosis . | Treatments prior to As2O3 . | Disease status at As2O3 . | Treatments after As2O3 . | Outcome . | Survival after As2O3 . | As2O3 resistance . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 61 | M | M3v | A+CT | Rel1 | (−) | D | 6 y, 1 mo | + |
| 2 | 35 | M | M3 | A+CT | Rel1 | sib-PBSCT | A | 3 y, 8 mo | − |
| 3 | 30 | M | M3 | A+CT | Rel2 | auto-PBSCT | A | 6 y, 9 mo | − |
| 4 | 41 | M | M3 | A+CT | Rel1 | auto-PBSCT | A | 5 y, 8 mo | − |
| 5 | 62 | M | M3 | A+CT, HD-Ara-C | Rel3 | CBT | D | 10 mo | − |
| 6 | 42 | F | M3 | A+CT, aPBSCT | Rel2 | CBT | D | 4 mo | + |
| 7 | 46 | F | M3 | A+CT | 2nd CR | auto-PBSCT | A | 6 y, 7 mo | − |
| 8 | 54 | F | M3 | A+CT | Rel2 | auto-PBSCT | A | 5 y, 9 mo | − |
| 9 | 19 | M | M3 | A+CT | Rel1 | UR-BMT | A | 6 y, 1 mo | − |
| 10 | 42 | M | M3 | A+CT, UR-BMT | Rel3 | DLI | A | 6 y | − |
| 11 | 61 | M | M3v | A+CT | Rel1 | (−) | D | 4 mo | − |
| 12 | 48 | M | M3 | A+CT, HD-Ara-C | Rel2 | auto-PBSCT | A | 4 y, 9 mo | − |
| 13 | 39 | M | M3v | A+CT, UR-BMT | Rel3 | CBT | D | 5 mo | − |
| 14 | 20 | M | M3 | A+CT | Rel1 | auto-PBSCT | A | 4 y, 9 mo | − |
| 15 | 36 | M | M3 | A+CT | Rel1 | auto-PBSCT | A | 4 y, 2 mo | − |
Fifteen patients were treated with As2O3 at Nagoya University Hospital during the period of January 2000–December 2008. Outcomes were confirmed on December 1, 2009. Patients 5, 6, and 13 received cord blood transplantation after As2O3. Patients 5 and 13 died of complications of transplantation without any relapse sign. Patient 6 died of relapse just after transplantation. Patient 11 died of brain bleeding due to APL relapse with disseminated intravascular coagulation.
Rel1 through 3 indicates the first to third relapse; A+CT, ATRA with combination chemotherapy; PBSCT, peripheral blood stem cell transplantation; CBT, cord blood transplantation; BMT, bone marrow transplantation; D, dead; and A, alive.